A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) (NCT07318558)
A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced Non-HRD Positive Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOTov85/GOG-3102)
🩺 Plain-English Summary (8th-Grade Level)
Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is used after another therapy to keep the cancer from growing, spreading, or coming back. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread. * Observation, which is watching to see if cancer grows or worsens The study medicine, sacituzumab tirumotecan (also called sac-TMT), is a targeted therapy. The goal of this study is to learn if people who receive sac-TMT maintenance treatment with or without bevacizumab live longer without the cancer getting worse than people who receive standard care.
Who can join: Review the eligibility criteria below.
Location: University of Alabama - Birmingham ( Site 0058) — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (159 Sites)
Showing the first 25 of 159 sites.
- University of Alabama - Birmingham ( Site 0058) — Birmingham, Alabama
- John Muir Health Cancer Center ( Site 0069) — Walnut Creek, California
- Mount Sinai Cancer Center ( Site 0029) — Miami Beach, Florida
- Orlando Health Winnie Palmer Hospital for Women and Babies ( Site 0085) — Orlando, Florida
- Winship Cancer Institute of Emory University ( Site 0037) — Atlanta, Georgia
- Illinois Cancer Specialists (ICS) ( Site 8009) — Arlington Heights, Illinois
- Parkview Research Center at Parkview Regional Medical Center ( Site 0055) — Fort Wayne, Indiana
- Franciscan Health Indianapolis ( Site 0081) — Indianapolis, Indiana
- Women's Cancer Care ( Site 0018) — Covington, Louisiana
- Maine Medical Center Research Institute-MaineHealth/Maine Medical Partners - GynOnc ( Site 0060) — Scarborough, Maine
- Maryland Oncology Hematology, P.A. ( Site 8002) — Columbia, Maryland
- Nebraska Methodist Hospital ( Site 0004) — Omaha, Nebraska
- University Of Nebraska Medical Center ( Site 0035) — Omaha, Nebraska
- The Center of Hope ( Site 0025) — Reno, Nevada
- Womens Cancer Care Associates, LLC ( Site 0023) — Albany, New York
- Duke Cancer Center ( Site 0012) — Durham, North Carolina
- University of Cincinnati Medical Center ( Site 0042) — Cincinnati, Ohio
- Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0007) — Tulsa, Oklahoma
- Hospital of the University of Pennsylvania ( Site 0071) — Philadelphia, Pennsylvania
- Women & Infants Hospital ( Site 0001) — Providence, Rhode Island
- West Cancer Center and Research Institute ( Site 0013) — Germantown, Tennessee
- University of Tennessee Medical Center ( Site 0087) — Knoxville, Tennessee
- Henry-Joyce Cancer Clinic ( Site 0011) — Nashville, Tennessee
- Virginia Cancer Specialists (VCS) ( Site 8012) — Fairfax, Virginia
- Virginia Oncology Associates (VOA) ( Site 8013) — Norfolk, Virginia
📞 Contact the Study Coordinator
Phone: (888) 577-8839
Email: Trialsites@msd.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ovarian Neoplasms
- A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy — Tempe, Arizona
- A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer — Anchorage, Alaska
- BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer — Durham, North Carolina
- Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants — New York, New York
- Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer — Little Rock, Arkansas
- A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) — Randwick, New South Wales
Explore by condition: All Ovarian Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.